MX2014003260A - Esteroides de plantas y usos de los mismos. - Google Patents

Esteroides de plantas y usos de los mismos.

Info

Publication number
MX2014003260A
MX2014003260A MX2014003260A MX2014003260A MX2014003260A MX 2014003260 A MX2014003260 A MX 2014003260A MX 2014003260 A MX2014003260 A MX 2014003260A MX 2014003260 A MX2014003260 A MX 2014003260A MX 2014003260 A MX2014003260 A MX 2014003260A
Authority
MX
Mexico
Prior art keywords
drug
conjugate
inhibitor
agonist
compound
Prior art date
Application number
MX2014003260A
Other languages
English (en)
Spanish (es)
Inventor
Michael Davidson
John F Arnett
Sadik Elshani
Roelof Rongen
Original Assignee
Davidson Lopez Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Davidson Lopez Llc filed Critical Davidson Lopez Llc
Publication of MX2014003260A publication Critical patent/MX2014003260A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014003260A 2011-09-16 2012-09-14 Esteroides de plantas y usos de los mismos. MX2014003260A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161535661P 2011-09-16 2011-09-16
US201261675966P 2012-07-26 2012-07-26
PCT/US2012/055549 WO2013040441A1 (en) 2011-09-16 2012-09-14 Plant steroids and uses thereof

Publications (1)

Publication Number Publication Date
MX2014003260A true MX2014003260A (es) 2014-09-08

Family

ID=47883793

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003260A MX2014003260A (es) 2011-09-16 2012-09-14 Esteroides de plantas y usos de los mismos.

Country Status (16)

Country Link
US (2) US10086082B2 (enExample)
EP (1) EP2755660B1 (enExample)
JP (2) JP6035338B2 (enExample)
KR (1) KR20140093661A (enExample)
CN (2) CN109384825A (enExample)
AU (1) AU2012308332A1 (enExample)
BR (1) BR112014006222A2 (enExample)
CA (1) CA2848979C (enExample)
EA (1) EA201490637A1 (enExample)
HK (1) HK1200358A1 (enExample)
IL (1) IL231541A0 (enExample)
IN (1) IN2014CN02688A (enExample)
MX (1) MX2014003260A (enExample)
PH (1) PH12014500596A1 (enExample)
SG (1) SG11201400652UA (enExample)
WO (1) WO2013040441A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015011948A (es) 2013-03-08 2015-12-09 Allergan Inc Antibioticos conjugados directamente relacionados con farmacos esteroides.
WO2014138437A1 (en) * 2013-03-08 2014-09-12 Allergan, Inc. Steroid conjugates
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
US10238664B2 (en) 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
WO2018132676A1 (en) * 2017-01-13 2018-07-19 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR102139678B1 (ko) * 2017-11-24 2020-07-31 전북대학교 산학협력단 N-아세틸 또는 n-아실 아미노산을 포함하는 아토피 또는 가려움증 치료용 조성물
CN110051674A (zh) * 2018-07-26 2019-07-26 中国人民解放军空军军医大学第一附属医院 豆甾醇在制备治疗胃癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052029A1 (en) * 1999-03-04 2000-09-08 Eugene Science Inc. Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same
SI1189924T1 (en) * 1999-06-23 2005-02-28 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
AU2002252387A1 (en) * 2001-03-14 2002-09-24 Lipogenics, Inc. Novel anti-inflammatory compositions and methods of use
WO2002089820A1 (en) * 2001-05-09 2002-11-14 Mediplex Corporation Formulation of amphiphilic heparin derivatives for enhancing mucosal absorption
SE0103765D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab New use
US20040236125A1 (en) * 2002-09-25 2004-11-25 Forbes Medi-Tech Inc. Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation
WO2004095926A2 (en) 2003-04-28 2004-11-11 Monsanto Technology, Llc Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield
US20050234025A1 (en) * 2004-04-20 2005-10-20 Forbes Medi-Tech Inc. Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
EP1861072A2 (en) * 2005-03-14 2007-12-05 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
AU2007299705B2 (en) * 2006-09-22 2012-09-06 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
CA2669355C (en) * 2006-11-06 2012-10-30 Jina Pharmaceuticals, Inc. Guggulphospholipid methods and compositions
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
RU2012138047A (ru) * 2010-03-02 2014-04-10 Имадженетикс, Инк. Композиции, содержащие миристиновую кислоту, и их применения

Also Published As

Publication number Publication date
KR20140093661A (ko) 2014-07-28
CN103987390A (zh) 2014-08-13
JP2017019871A (ja) 2017-01-26
PH12014500596A1 (en) 2014-04-21
EP2755660A1 (en) 2014-07-23
JP6035338B2 (ja) 2016-11-30
IN2014CN02688A (enExample) 2015-07-03
EP2755660B1 (en) 2019-11-06
JP2014526515A (ja) 2014-10-06
EP2755660A4 (en) 2015-03-18
US20150141390A1 (en) 2015-05-21
WO2013040441A1 (en) 2013-03-21
CA2848979A1 (en) 2013-03-21
US20190083632A1 (en) 2019-03-21
CN109384825A (zh) 2019-02-26
US10086082B2 (en) 2018-10-02
EA201490637A1 (ru) 2014-11-28
HK1200358A1 (en) 2015-08-07
IL231541A0 (en) 2014-04-30
SG11201400652UA (en) 2014-09-26
AU2012308332A1 (en) 2014-04-10
CA2848979C (en) 2019-11-05
BR112014006222A2 (pt) 2017-04-11

Similar Documents

Publication Publication Date Title
MX2014003260A (es) Esteroides de plantas y usos de los mismos.
Hwang et al. Yam-derived exosome-like nanovesicles stimulate osteoblast formation and prevent osteoporosis in mice
EP1893191B1 (en) Medicinal acidic cannabinoids
Toegel et al. Caesalpinia sappan extract inhibits IL1β-mediated overexpression of matrix metalloproteinases in human chondrocytes
Wallert et al. The vitamin E derivative garcinoic acid from Garcinia kola nut seeds attenuates the inflammatory response
Wang et al. Fluorous‐tagged peptide nanoparticles ameliorate acute lung injury via lysosomal stabilization and inflammation inhibition in pulmonary macrophages
Navarro-Nunez et al. Thromboxane a2 receptor antagonism by flavonoids: Structure− activity relationships
Nachliely et al. Dimethyl fumarate and vitamin D derivatives cooperatively enhance VDR and Nrf2 signaling in differentiating AML cells in vitro and inhibit leukemia progression in a xenograft mouse model
Shi et al. Piperlongumine attenuates high calcium/phosphate-induced arterial calcification by preserving P53/PTEN signaling
Li et al. Eriobotrya japonica leaf triterpenoid acids ameliorate metabolic syndrome in C57BL/6J mice fed with high-fat diet
Huang et al. Triterpenoids from functional mushroom Ganoderma resinaceum and the novel role of Resinacein S in enhancing the activity of brown/beige adipocytes
Wang et al. Inhibitory activity of linarin on osteoclastogenesis through receptor activator of nuclear factor κB ligand-induced NF-κB pathway
Lee et al. Extract of Alnus japonica prevents dexamethasone-induced muscle atrophy in mice
Zhang et al. A flavonoids compound inhibits osteoclast differentiation by attenuating RANKL induced NFATc-1/c-Fos induction
Li et al. Human and murine hepatic sterol-12-α-hydroxylase and other xenobiotic metabolism mRNA are upregulated by soy isoflavones
CN107746403A (zh) 系列开环松香烷型二萜类化合物及其药物组合物与其在制药中的应用
CN105837592B (zh) 间苯三酚骈松香烷二萜类化合物及其制备方法和药物用途
Chen et al. Gypenoside, the main active compound of Gynostemma pentaphyllum, mitigates the diabetic nephropathy through down-regulating mTOR
Cui et al. Osteon Myospalacem Baileyi attenuates osteoclast differentiation through RANKL induced NFAT pathways
Peletier et al. Fueling Stenosis: The integral role of PFKFB3-mediated glycolysis in Lp (a)-induced Valve Inflammation
Peletier et al. Fuelling aortic stenosis: the integral role of 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3-mediated glycolysis in Lp (a)-induced valve inflammation
El-Shehawi et al. Screening of Salsola imbricata extract impacts against acrylamide induced hepatic toxicity in rats through the regulation of different global gene expression
WO2019236754A1 (en) Compounds and methods for the treatment of autism spectrum disorder and other neurological or psychiatric disorders
Fiebich et al. Cannabidiol markedly alleviates
Kasekarn The Inhibitory Effects of Rosmarinic Acid on RANKL-Mediated Osteoclastogenesis, F-actin Ring Formation and Bone Resorption through the Suppression of the NF-κB Signaling Pathway

Legal Events

Date Code Title Description
FA Abandonment or withdrawal